Review




Structured Review

Humacyte Inc human acellular vessel (humacyte hav)
Human Acellular Vessel (Humacyte Hav), supplied by Humacyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+acellular+vessel+(humacyte+hav)/human+acellular+vessel++hav+/pmc11579887__jamasurg___e244893___s001-3568-11-15
Average 90 stars, based on 1 article reviews
human acellular vessel (humacyte hav) - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Labeling:

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Rationale: Humacyte is developing an acellular, human tissue engineered vascular conduit, the human acellular vessel (HAV), to provide an alternative to synthetic materials and to autologous grafts for traumatic vascular damage.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: The investigational medicinal product (IMP) is a Humacyte Human Acellular Vessel (HAV), which is a tissue-engineered vascular prosthesis for arterial bypass or reconstruction in patients with peripheral arterial disease or peripheral arterial trauma.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the Humacyte Human Acellular Vessel (HAV) Page 409 of 458 Humacyte, Inc Confidential 29 December 2015 Study No. CLN-PRO-V005 Version 1.0 13 of 61 7.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: 6.1 PRODUCT DESCRIPTION................................................................................................................. 34 6.2 MANUFACTURER OF THE IMP ......................................................................................................... 34 6.3 PACKAGING, STORAGE, AND LABELING ........................................................................................... 34 6.4 IMPLANTATION OF THE HUMACYTE HUMAN ACELLULAR VESSEL (HAV) ............................................ 35 6.5 IMP ACCOUNTABILITY PROCEDURES .............................................................................................. 35 6.6 ASSESSMENT OF PATIENT COMPLIANCE WITH IMP .......................................................................... 36 6.7 PRIOR AND CONCOMITANT MEDICATIONS ....................................................................................... 36 6.8 ESSENTIAL, PRECAUTIONARY AND PROHIBITED MEDICATIONS ......................................................... 37 6.8.1 Essential Medications .............................................................................................................. 37 6.8.2 Restricted Medications ............................................................................................................ 37

Article Title: A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma
Article Snippet: Subjects will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the Humacyte Human Acellular Vessel (HAV).

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Page 325 of 458 Humacyte, Inc Confidential 24 October 2016 Study No. CLN-PRO-V005 Version 2.0 13 of 66 Study Design Prospective, multicenter, single arm, non-randomized study Investigational Device/Intervention Description Patients will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Humacyte has developed an acellular, human tissue engineered vascular conduit, the human acellular vessel (HAV), to provide an alternative to synthetic materials and to autologous grafts in the repair of traumatic vascular damage.

Medications:

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Rationale: Humacyte is developing an acellular, human tissue engineered vascular conduit, the human acellular vessel (HAV), to provide an alternative to synthetic materials and to autologous grafts for traumatic vascular damage.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: The investigational medicinal product (IMP) is a Humacyte Human Acellular Vessel (HAV), which is a tissue-engineered vascular prosthesis for arterial bypass or reconstruction in patients with peripheral arterial disease or peripheral arterial trauma.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the Humacyte Human Acellular Vessel (HAV) Page 409 of 458 Humacyte, Inc Confidential 29 December 2015 Study No. CLN-PRO-V005 Version 1.0 13 of 61 7.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: 6.1 PRODUCT DESCRIPTION................................................................................................................. 34 6.2 MANUFACTURER OF THE IMP ......................................................................................................... 34 6.3 PACKAGING, STORAGE, AND LABELING ........................................................................................... 34 6.4 IMPLANTATION OF THE HUMACYTE HUMAN ACELLULAR VESSEL (HAV) ............................................ 35 6.5 IMP ACCOUNTABILITY PROCEDURES .............................................................................................. 35 6.6 ASSESSMENT OF PATIENT COMPLIANCE WITH IMP .......................................................................... 36 6.7 PRIOR AND CONCOMITANT MEDICATIONS ....................................................................................... 36 6.8 ESSENTIAL, PRECAUTIONARY AND PROHIBITED MEDICATIONS ......................................................... 37 6.8.1 Essential Medications .............................................................................................................. 37 6.8.2 Restricted Medications ............................................................................................................ 37

Article Title: A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma
Article Snippet: Subjects will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the Humacyte Human Acellular Vessel (HAV).

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Page 325 of 458 Humacyte, Inc Confidential 24 October 2016 Study No. CLN-PRO-V005 Version 2.0 13 of 66 Study Design Prospective, multicenter, single arm, non-randomized study Investigational Device/Intervention Description Patients will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Humacyte has developed an acellular, human tissue engineered vascular conduit, the human acellular vessel (HAV), to provide an alternative to synthetic materials and to autologous grafts in the repair of traumatic vascular damage.

Clarification Assay:

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Rationale: Humacyte is developing an acellular, human tissue engineered vascular conduit, the human acellular vessel (HAV), to provide an alternative to synthetic materials and to autologous grafts for traumatic vascular damage.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: The investigational medicinal product (IMP) is a Humacyte Human Acellular Vessel (HAV), which is a tissue-engineered vascular prosthesis for arterial bypass or reconstruction in patients with peripheral arterial disease or peripheral arterial trauma.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the Humacyte Human Acellular Vessel (HAV) Page 409 of 458 Humacyte, Inc Confidential 29 December 2015 Study No. CLN-PRO-V005 Version 1.0 13 of 61 7.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: 6.1 PRODUCT DESCRIPTION................................................................................................................. 34 6.2 MANUFACTURER OF THE IMP ......................................................................................................... 34 6.3 PACKAGING, STORAGE, AND LABELING ........................................................................................... 34 6.4 IMPLANTATION OF THE HUMACYTE HUMAN ACELLULAR VESSEL (HAV) ............................................ 35 6.5 IMP ACCOUNTABILITY PROCEDURES .............................................................................................. 35 6.6 ASSESSMENT OF PATIENT COMPLIANCE WITH IMP .......................................................................... 36 6.7 PRIOR AND CONCOMITANT MEDICATIONS ....................................................................................... 36 6.8 ESSENTIAL, PRECAUTIONARY AND PROHIBITED MEDICATIONS ......................................................... 37 6.8.1 Essential Medications .............................................................................................................. 37 6.8.2 Restricted Medications ............................................................................................................ 37

Article Title: A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma
Article Snippet: Subjects will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of the Humacyte Human Acellular Vessel (HAV).

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Page 325 of 458 Humacyte, Inc Confidential 24 October 2016 Study No. CLN-PRO-V005 Version 2.0 13 of 66 Study Design Prospective, multicenter, single arm, non-randomized study Investigational Device/Intervention Description Patients will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.

Article Title: Bioengineered Human Arteries for the Repair of Vascular Injuries
Article Snippet: Humacyte has developed an acellular, human tissue engineered vascular conduit, the human acellular vessel (HAV), to provide an alternative to synthetic materials and to autologous grafts in the repair of traumatic vascular damage.



Similar Products

90
Humacyte Inc human acellular vessel (humacyte hav)
Human Acellular Vessel (Humacyte Hav), supplied by Humacyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+acellular+vessel+(humacyte+hav)/human+acellular+vessel++hav+/pmc11579887__jamasurg___e244893___s001-3568-11-15
Average 90 stars, based on 1 article reviews
human acellular vessel (humacyte hav) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Humacyte Inc human acellular vessel (hav, humacyte, inc, durham, nc)
Human Acellular Vessel (Hav, Humacyte, Inc, Durham, Nc), supplied by Humacyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+acellular+vessel+(humacyte+hav)/human+acellular+vessel++hav+/pmc07270716-3-0-4
Average 90 stars, based on 1 article reviews
human acellular vessel (hav, humacyte, inc, durham, nc) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results